CP533536

an EP2 receptor-selective prostaglandin E2 agonist that induces bone healing; structure in first source

Also Known As:

(3-((4-tert-butylbenzyl)-(pyridine-3-sulfonylamino)methyl)phenoxy)acetic acid; CP-533,536

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Bone Fractures (Bone Fracture) 10/01/2008 - "CP-533,536, (3-{[(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (1), an EP2 receptor-selective prostaglandin E2 agonist, is being developed to aid in the healing of bone fractures. "
2.	Urethral Obstruction 05/01/2016 - "We investigated the effect of the selective prostaglandin E2 EP2 receptor agonist CP-533,536 on voiding efficiency in rats with midodrine-induced functional urethral obstruction. " 05/01/2016 - "Effect of Selective Prostaglandin E2 EP2 Receptor Agonist CP-533,536 on Voiding Efficiency in Rats with Midodrine-Induced Functional Urethral Obstruction."
3.	Femoral Fractures (Femoral Fracture) 11/01/2003 - "In the rat femoral fracture model, CP-533,536 in PLGH matrix at doses of 0.05, 0.5, and 5 mg dose-dependently increased callus size, density, and strength compared with PLGH matrix alone. " 11/01/2003 - "Finally, the ability of CP-533,536 in PLGH matrix in enhancing fracture healing was tested using the rat femoral fracture model. "